Elimination of rubella and congenital rubella syndrome in the Americas
- PMID: 21954249
- DOI: 10.1093/infdis/jir472
Elimination of rubella and congenital rubella syndrome in the Americas
Abstract
In 2003, the Pan American Health Organization (PAHO) adopted a resolution calling for rubella and congenital rubella syndrome (CRS) elimination in the Americas by the year 2010. To accomplish this goal, PAHO advanced a rubella and CRS elimination strategy including introduction of rubella-containing vaccines into routine vaccination programs accompanied by high immunization coverage, interruption of rubella transmission through mass vaccination of adolescents and adults, and strengthened surveillance for rubella and CRS. The rubella elimination strategies were aligned with the successful measles elimination strategies. By the end of 2009, all countries routinely vaccinated children against rubella, an estimated 450 million people had been vaccinated against measles and rubella in supplementary immunization activities, and rubella transmission had been interrupted. This article describes how the region eliminated rubella and CRS.
Similar articles
-
Progress toward elimination of rubella and congenital rubella syndrome--the Americas, 2003-2008.MMWR Morb Mortal Wkly Rep. 2008 Oct 31;57(43):1176-9. MMWR Morb Mortal Wkly Rep. 2008. PMID: 18971920
-
Guidelines for the documentation and verification of measles, rubella, and congenital rubella syndrome elimination in the region of the Americas.J Infect Dis. 2011 Sep 1;204 Suppl 2:S683-9. doi: 10.1093/infdis/jir471. J Infect Dis. 2011. PMID: 21954267
-
Elimination of rubella and congenital rubella syndrome: we did it together! Foreword.J Infect Dis. 2011 Sep 1;204 Suppl 2:i. doi: 10.1093/infdis/jir556. J Infect Dis. 2011. PMID: 21954240 No abstract available.
-
Congenital rubella syndrome: progress and future challenges.Expert Rev Vaccines. 2009 Mar;8(3):323-31. doi: 10.1586/14760584.8.3.323. Expert Rev Vaccines. 2009. PMID: 19249974 Review.
-
Targeting rubella for elimination.Indian J Public Health. 2012 Oct-Dec;56(4):269-72. doi: 10.4103/0019-557X.106413. Indian J Public Health. 2012. PMID: 23354136 Review.
Cited by
-
[Lessons learned in the implementation of measles and rubella vaccination campaigns in the AmericasLições aprendidas com a implementação de campanhas de vacinação contra sarampo e rubéola na Região das Américas].Rev Panam Salud Publica. 2025 Mar 20;49:e24. doi: 10.26633/RPSP.2025.24. eCollection 2025. Rev Panam Salud Publica. 2025. PMID: 40115247 Free PMC article. Spanish.
-
Seroprevalence of anti-mumps virus IgG antibody titer and voluntary mumps vaccination coverage in young adults in Japan.Hum Vaccin Immunother. 2021 Sep 2;17(9):3153-3155. doi: 10.1080/21645515.2021.1913967. Epub 2021 Apr 20. Hum Vaccin Immunother. 2021. PMID: 33877956 Free PMC article.
-
Strategies for elimination of rubella in pregnancy and of congenital rubella syndrome in high and upper-middle income countries.J Prev Med Hyg. 2020 Apr 2;61(1):E98-E108. doi: 10.15167/2421-4248/jpmh2020.61.1.1310. eCollection 2020 Mar. J Prev Med Hyg. 2020. PMID: 32490275 Free PMC article. Review.
-
Multiplexed VaxArray immunoassay for rapid antigen quantification in measles and rubella vaccine manufacturing.Vaccine X. 2021 Sep 20;9:100113. doi: 10.1016/j.jvacx.2021.100113. eCollection 2021 Dec. Vaccine X. 2021. PMID: 34622199 Free PMC article.
-
Development of a District-Level Programmatic Assessment Tool for Risk of Measles Virus Transmission.Risk Anal. 2017 Jun;37(6):1052-1062. doi: 10.1111/risa.12409. Epub 2015 May 15. Risk Anal. 2017. PMID: 25976980 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources